Takeda Pharmaceutical Co Ltd will accept initial bids for its 70 percent stake in a chemicals company through Aug. 16, with potential suitors including CVC Capital Partners Ltd and Carlyle Group Ltd, sources told Reuters.
Takeda, Japan’s largest drugmaker by market value, aims to sell its holding in Wako Pure Chemicals Industries Ltd to streamline operations, four people familiar with the plan said, declining to be identified as the matter was private.
The winning bidder would likely buy out the remaining shareholders, taking the deal over 100 billion yen ($957.95 million), the people said.
The drugmaker is likely to receive an aggressive bid from Fujifilm Holdings Corp, which is seeking to expand its medical business and already owns 9.5 percent of Wako Pure, the people said.
Buyout firm Permira is also among companies set to bid, they said.
Takeda, Carlyle, CVC, Fujifilm and Permira declined to comment.
Takeda has invited a number of the global buyout firms to the bid for its stake in the Osaka-based maker of laboratory chemicals and clinical diagnostic reagents, which had sales of 75.7 billion yen last year, the people said.
A deal would follow the December sale of Takeda’s portfolio of respiratory drugs to Britain’s AstraZeneca PLC for $575 million. ($1 = 104.3900 yen)
By Junko Fujita
Source: Reuters
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”
